MicuRx Pharmaceuticals

company

About

MicuRx discovers and develops novel antimicrobials to treat drug-resistant infections and other diseases of significant unmet medical need

  • 101 - 250

Details

Last Funding Type
Series C
Last Funding Money Raised
$55M
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2007
Number Of Employee
101 - 250
Operating Status
Active

MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient scientific resources in China. Shanghai MicuRx was established and as of 2021 commercializes our agent, contezolid, in China. Global clinical studies are on-going.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$55M ¥1B
MicuRx Pharmaceuticals has raised a total of $55M ¥1B in funding over 2 rounds. Their latest funding was raised on Dec 21, 2020 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 21, 2020 Series E ¥700M 1 Detail
Aug 5, 2020 Series D ¥300M 1 Detail
Sep 26, 2016 Series C $55M 1 Detail

Investors

Number of Lead Investors
Number of Investors
3
MicuRx Pharmaceuticals is funded by 3 investors. Zhongtai Venture Capital and Sinopharm-CICC are the most recent investors.
Investor Name Lead Investor Funding Round
Zhongtai Venture Capital Series E
Sinopharm-CICC Series D
GP TMT Capital Series C